Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Reported, And Analysts Assigned A US$7.67 Price Target

Simply Wall StAug 11 08:52 ET

Coherus BioSciences Second Quarter 2024 Earnings: Beats Expectations

Yahoo FinanceAug 10 08:47 ET

Strong Financial Performance and Market Share Growth Underpin Buy Rating for Coherus Biosciences

TipRanksAug 9 09:59 ET · Ratings

Buy Rating Justified by Coherus Biosciences' Strong Udenyca Sales and Promising Pipeline

TipRanksAug 9 07:19 ET · Ratings

Express News | Coherus BioSciences Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results

BenzingaAug 8 17:19 ET

Express News | Coherus BioSciences Sees FY24 R&D And SG&A Expenses $250M-$265M

BenzingaAug 8 17:10 ET